Data from animal experiments suggest that treatment with PPAR-γ agonists reduce the ability of antigen presenting cells to activate T cells and induce eosinophilic airway inflammation – inflammation characteristic of TH2 high asthma [14]. This evidence concerns the gene PPARG and asthma.